603658 Stock Overview
Engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for 603658 from our risk checks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Autobio Diagnostics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥41.94 |
| 52 Week High | CN¥58.70 |
| 52 Week Low | CN¥37.56 |
| Beta | 0.065 |
| 1 Month Change | -1.04% |
| 3 Month Change | 3.30% |
| 1 Year Change | -21.99% |
| 3 Year Change | -9.42% |
| 5 Year Change | -58.23% |
| Change since IPO | 33.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603658 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | 4.8% | 5.2% | 6.4% |
| 1Y | -22.0% | -6.5% | 8.5% |
Return vs Industry: 603658 underperformed the CN Medical Equipment industry which returned -6.3% over the past year.
Return vs Market: 603658 underperformed the CN Market which returned 7.9% over the past year.
Price Volatility
| 603658 volatility | |
|---|---|
| 603658 Average Weekly Movement | 3.7% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 603658 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603658's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 5,539 | Zeng Li Yang | www.autobio.com.cn |
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an automatic immunoassay analyzer; AutoLumo A2000 Plus, an automated chemiluminescence immunoassay analyzer; PHOmo microplate readers; LUmo microplate luminometers; and iWO and iWO-960 microplate washers.
Autobio Diagnostics Co., Ltd. Fundamentals Summary
| 603658 fundamental statistics | |
|---|---|
| Market cap | CN¥23.97b |
| Earnings (TTM) | CN¥1.27b |
| Revenue (TTM) | CN¥4.58b |
18.8x
P/E Ratio5.2x
P/S RatioIs 603658 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603658 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.58b |
| Cost of Revenue | CN¥1.62b |
| Gross Profit | CN¥2.96b |
| Other Expenses | CN¥1.69b |
| Earnings | CN¥1.27b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 18, 2025
| Earnings per share (EPS) | 2.23 |
| Gross Margin | 64.69% |
| Net Profit Margin | 27.78% |
| Debt/Equity Ratio | 6.6% |
How did 603658 perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield48%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 16:00 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Autobio Diagnostics Co., Ltd. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhe Sun | BofA Global Research |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Jin Zhang | China International Capital Corporation Limited |